

Home - MOP

[View all](#)

KISQALI® - ribociclib

[Product Information](#)

KESIMPTA®▼ - ofatumumab

[Product Information](#)

LEQVIO®▼ - inclisiran

[Product Information](#)

COSENTYX® - secukinumab in Dermatology

[Product information](#)

COSENTYX® - secukinumab in Rheumatology

[Product information](#)

JAKAVI® - ruxolitinib

[Product Information](#)

SCEMBLIX®▼ - asciminib

[Product Information](#)

FABHALTA®▼ - iptacopan

[Product information](#)

Reporting side-effects

If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. ▼ The medicine referred to in this material is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side-effects you may get. Please see www.mhra.gov.uk/yellowcard for instructions on how to report side-effects.

Reporting side-effects

If you get side-effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side-effects not listed in the information leaflet that comes in the pack. You can report side-effects via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

By reporting side-effects you can help provide more information on the safety of your medication.

Source URL: <https://www.pro.novartis.com/uk-en/public>